Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.

The enterprise value of the transaction is SEK 500 million, with potential for an additional earnout of up to SEK 130 million. Up to SEK 100 million of the purchase price can be paid in Aspo shares.

Aspo is a Finnish conglomerate that specializes in demanding B-to-B customers. Aspo creates value by owning and developing business operations sustainably and in the long term. Aspo has businesses in 16 different countries, and it employs a total of approximately 700 professionals.

Read the client’s press release here.

Vinge’s team mainly consisted of Jonas Johansson, Linus Adolfsson, Tim Axell (M&A), Karl-Gustaw Tobola (Banking and Finance), Mario Saad (Corporate Commercial), Ebba Svenburg, Jonna Skog (Employment) Johan Cederblad, Lina Österberg (Environment), Elis Almark, Carla Zachariasson (IT & GDPR), Karolina Cohrs (Real Estate), Daniel Wendelsson, Sebastian Örndahl, Dagne Sabockis, Hilda Ivarsson (FDI, EU, Competition and Regulatory) and Emma Emsjö (Transaction Support Coordinator).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026